ACADIA Pharmaceuticals Inc. Revenue Growth

Revenue Growth of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Revenue Growth growth rates and interactive chart. Year over year growth in total sales.


Highlights and Quick Summary

  • Revenue Growth for the quarter ending March 30, 2021 was 0.18 (a -20.68% decrease compared to previous quarter)
  • Year-over-year quarterly Revenue Growth decreased by -43.4%
  • Annual Revenue Growth for 2020 was 0.3 (a -41.2% decrease from previous year)
  • Annual Revenue Growth for 2019 was 0.52 (a -34.97% decrease from previous year)
  • Annual Revenue Growth for 2018 was 0.79 (a -87.24% decrease from previous year)
  • Twelve month Revenue Growth ending March 30, 2021 was 0.25 (a -16.97% decrease compared to previous quarter)
  • Twelve month trailing Revenue Growth decreased by -48.56% year-over-year
Trailing Revenue Growth for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
0.25 0.3 0.4 0.49
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Revenue Growth of ACADIA Pharmaceuticals Inc.

Most recent Revenue Growthof ACAD including historical data for past 10 years.

Interactive Chart of Revenue Growth of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Revenue Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 0.18
2020 0.23 0.27 0.32 0.43 0.3
2019 0.65 0.62 0.46 0.29 0.52
2018 0.37 0.64 0.87 2.2 0.79
2017 2.64 5.75 313.18 3820.5 6.21
2016 702.65 134.08 96.0 0.0 283.11
2015 -0.64 1.6 -0.96 -0.87 -0.49
2014 0.27 -0.94 -0.94 -0.93 -0.9
2013 -0.9 -0.93 -0.25 -0.07 -0.77
2012 -0.35 4.96 0.3 0.03 1.37
2011 -0.98 -0.75 -0.8 -0.8 -0.95
2010 19.0 -0.06 0.26 5.58

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.